Neurogene Secures $200M for Genetic Therapy Development
Company Announcements

Neurogene Secures $200M for Genetic Therapy Development

Neurogene ( (NGNE) ) has shared an update.

Neurogene Inc. has announced a $200 million private placement financing, involving top-tier healthcare funds, to support its innovative genetic therapies for rare neurological diseases. The proceeds are expected to fund the company into the second half of 2027, aiding in the development of its NGN-401 gene therapy for Rett syndrome and other projects. Neurogene aims to maximize the therapeutic impact with its EXACT™ platform, ensuring optimized efficacy and safety in its treatments.

Find detailed analytics on NGNE stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskNeurogene Reports Promising Interim Results for NGN-401 Trial
TheFlyNeurogene price target raised to $60 from $44 at Stifel
TheFlyNeurogene price target lowered to $60 from $65 at BMO Capital
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App